FLUTICASONE FUROATE

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Arnuity Ellipta®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
GlaxoSmithKline Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Asthma
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New listing (Minor)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2019 PBAC meeting
Opportunity for consumer comment:
Open 01/05/2019 and close 12/06/2019 (see PBS Website)
PBAC meeting:
Held on 10/07/2019
4PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – July 2019
Case ID
a020
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19